Atossa Therapeutics, Inc. - Common Stock (ATOS)
2.1300
+0.0100 (0.47%)
NASDAQ · Last Trade: Nov 10th, 3:48 AM EST
News & Press Releases
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Issued on behalf of Oncolytics Biotech Inc.
By Equity Insider · Via GlobeNewswire · March 19, 2026
ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Splitstocktwits.com
Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026.
Via Stocktwits · February 2, 2026
Get insights into the top gainers and losers of Friday's after-hours session.chartmill.com
Via Chartmill · January 16, 2026
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Trackstocktwits.com
Via Stocktwits · December 11, 2025
MicroMarvel - Atossa Therapeuticstalkmarkets.com
Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals
Via Talk Markets · April 6, 2024
Why Did ATOS Stock Jump 10% In Pre-Market Today?stocktwits.com
The U.S. Food and Drug Administration granted Orphan Drug Designation to its (Z)-Endoxifen therapy for DMD.
Via Stocktwits · January 16, 2026
Why Are Shares Of Atossa Therapeutics Up Today?benzinga.com
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.
Via Benzinga · December 11, 2025
Get insights into the top gainers and losers of Thursday's pre-market session.chartmill.com
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · December 11, 2025
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / August 29, 2025 / RedChip Companies will air interviews with NioCorp Developments Ltd. (Nasdaq:NB) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, August 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESS Newswire · August 29, 2025
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, August 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESS Newswire · August 1, 2025
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga.com
Via Benzinga · June 5, 2025
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, is pleased to invite investors to a webinar on May 22, 2025, at 4:15 p.m. ET.
Via ACCESS Newswire · May 20, 2025
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / May 2, 2025 / RedChip Companies will air interviews with Atossa Therapeutics, Inc. (Nasdaq:ATOS) and Ainos, Inc. (Nasdaq:AIMD) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESS Newswire · May 2, 2025
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · September 11, 2024
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024investorplace.com
ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024
3 Dirt-Cheap Drug Developers With Blockbuster Potentialinvestorplace.com
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
Via InvestorPlace · July 11, 2024
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025investorplace.com
If you understand the risks of penny stocks with upside, you may want to investigate these three stocks today.
Via InvestorPlace · July 3, 2024
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soarinvestorplace.com
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.
Via InvestorPlace · June 7, 2024
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Offinvestorplace.com
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation.
Via InvestorPlace · May 20, 2024
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024investorplace.com
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.
Via InvestorPlace · May 17, 2024
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024investorplace.com
ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radarinvestorplace.com
Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider.
Via InvestorPlace · May 9, 2024
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023investorplace.com
ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 1, 2024
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Marketinvestorplace.com
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.
Via InvestorPlace · January 16, 2024